What patients, podcasts, clinics, and forums are saying about peptides — labelled by source credibility and linked back to the graded clinical claim each story is being used to support. Use this when a patient asks "but I read that…".
Patients on semaglutide consistently describe a quieting of intrusive food thoughts within 1–4 weeks — predates measurable weight loss. Mechanistically plausible via central GLP-1R / hypothalamic ARC pathways.
Survey study and convergent anecdotal reports of decreased alcohol consumption on GLP-1 RAs; small RCTs underway. Treat as hypothesis-generating, not a treatment indication.
Frequently amplified by influencers; do not promise this effect to patients.
Recurring claim that 4–8 weeks of subQ BPC-157 around the injury site resolves chronic tendinopathy. No published human RCTs; rat data are consistent but came primarily from a single research group.
Vendor case series of '90% improved' patients with no controls, no imaging, no follow-up. Useful as a teaching example of marketing language vs. evidence-grade language.
Use this with patients to model how to evaluate a clinic claim.
Subjective deeper sleep within 2 weeks of evening CJC-1295 + ipamorelin. Mechanistic plausibility (GH pulse aligns with stage-3 sleep) is reasonable; no controlled polysomnography data exist.
Documented changes in nevi, nausea, and pigmentation patterns from unregulated melanotan-II. Anecdotal pattern matches a real safety signal published in BMJ.
Frequent claims that intranasal oxytocin improves relationships, empathy, and trust. Leng & Ludwig's 'myths and delusions' review shows the human social-cognition literature is deeply inconsistent.
Convergent forum reports of improved focus and reduced acute stress. Russian licensed indications are stroke recovery and cognitive disorders; Western RCT data are essentially absent.
Good example of reasonable-sounding mechanism + active vendor market + zero rigorous Western evidence.
Heavy anecdotal reporting of better sleep and 'feeling younger' on Khavinson bioregulator peptides. Most of the underlying corpus comes from a single institution; no rigorous Western trials replicate the longevity claims.
Useful when patients ask about peptides marketed in longevity circles.
Subjective improvement in skin texture and fine lines from topical GHK-Cu. Consistent with the small controlled cosmetic studies; systemic 'anti-aging' claims for injected GHK-Cu are not supported.